Breaking News Instant updates and real-time market news.

TCEHY

Tencent

$0.00

(0.00%)

, AAPL

Apple

$214.49

-1.89 (-0.87%)

06:41
10/12/18
10/12
06:41
10/12/18
06:41

Hackers use stolen Apple IDs to steal cash in China, Bloomberg reports

Ant Financial's Alipay and Tencent Holdings (TCEHY) warned that cyber-attackers used stolen Apple (AAPL) IDs to break into customers' accounts and made off with an unknown amount of cash, Bloomberg reports, citing the companies. Alipay, whose parent company is the financial affiliate to Alibaba (BABA), said that it contacted Apple, it is working to get to the bottom of the breach and warned users that have linked Apple identities to any payment services to lower transaction limits to avoid additional losses. Tencent also said it reached out to Apple. Reference Link

TCEHY

Tencent

$0.00

(0.00%)

AAPL

Apple

$214.49

-1.89 (-0.87%)

BABA

Alibaba

$142.03

3.64 (2.63%)

  • 28

    Oct

TCEHY Tencent
$0.00

(0.00%)

08/16/18
JEFF
08/16/18
NO CHANGE
Target $90
JEFF
Buy
China approval freeze creates buying opportunity in Activision, says Jefferies
Jefferies analyst Timothy O'Shea said he views China having frozen mobile game approvals as a temporary problem and "mostly a non-issue" as only the monetization approval process has been frozen, not the content approval process, and he note administrators are already implementing a fast-track approval process to alleviate the problem. Activision Blizzard's (ATVI) upcoming Call of Duty mobile game was expected to launch in China this year, but O'Shea said this is a smaller game that is not in his estimates, adding that Tencent (TCEHY) gets 70% of the revenue under its deal for the game. Activision has a pipeline of new mobile games coming that he would still expect to launch in China over time and O'Shea sees the 15% pullback in the game maker's shares in the last month as a buying opportunity, he tells investors. He maintains a Buy rating and $90 price target on Activision Blizzard shares.
08/20/18
NOMU
08/20/18
NO CHANGE
NOMU
Buy
China watchdogs said to likely restart game reviews soon, says Nomura Instinet
Nomura Instinet analyst Jialong Shi noted that over the weekend posts on Weibo said China's online game watchdogs will likely restart game reviews as early as September, adding that a few of his online gaming contacts have also heard lately from relevant watchdogs that the review of new games should restart soon. If game reviews do resume in September, Tencent's (TCEHY) PUBG Mobile and Fortnite are likely to receive licenses for monetization in Q4 at the earliest, said Shi, who believes Tencent and NetEase (NTES) would benefit from improved sentiment and outlooks if Chinese regulators restart reviews.
08/22/18
LEHM
08/22/18
NO CHANGE
Target $55
LEHM
Overweight
Tencent price target lowered to $55 from $59 at Barclays
Barclays analyst Gregory Zhao lowered his price target for Tencent Holdings to $55 following the company's Q2 results to reflect the impact from monetization approval delay to mobile gaming revenue as well as the negative efforts to interest revenue due to the deposit rate increase. The analyst keeps an Overweight rating on the shares.
09/13/18
GSCO
09/13/18
INITIATION
Target $31.9
GSCO
Buy
Pinduoduo initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Piyush Mubayi started Pinduoduo (PDD) with a Buy rating and $31.90 price target, identifying it as the "fastest-growing internet company in the world" in terms of revenue growth. He sees Pinduoduo being well positioned to benefit from continuous growth of China e-commerce based on its popular app and Tencent's (TCEHY) social networks.
AAPL Apple
$214.49

-1.89 (-0.87%)

10/09/18
10/09/18
DOWNGRADE

Neutral
Coherent downgraded to Neutral on OLED timing, industrial malaise at Longbow
As previously reported, Longbow analyst Joe Wittine downgraded Coherent (COHR) Neutral from Buy based upon a potentially elongating OLED investment cycle. Wittine views Apple's (AAPL) iPhone XR/LCD dynamic as partially responsible for this extension. Should advanced LCD devices prove to have a longer shelf life, the investment cycle will face extensions, he contends. The analyst also cited the weakening seen in his Q3 industrial laser survey confirmed by IPG Photonics' (IPGP) Q3 preannouncement last week.
10/09/18
VERF
10/09/18
INITIATION
Target $175
VERF
Sell
Apple initiated with a Sell at Vertical Group
Vertical Group initiated Apple with a Sell and $175 price target.
10/10/18
BFIN
10/10/18
NO CHANGE
BFIN
BlueFin checks show Lumentum received increased orders from Apple
BlueFin analysts John Donovan and Steve Mullane say their firm's latest supply chain checks suggest "strong and stable" iPhone demand. While unit demand has not changed, the mix to higher storage models has increased, which should benefit Toshiba (TOSBF), Samsung (SSNLF), and Micron Technology (MU), Donovan and Mullane tell investors in a research note. Further, BlueFin's latest checks reveal Lumentum (LITE) has received increased orders recently while competitors II-VI (IIVI) and Finisar (FNSR) continue to focus on securing second-source positioning. The latest on the two latter companies is mixed, but overall "encouraging," the analysts contend. As far as the rumors that Apple is exploring internal VCSEL development, they believe this is "more of a negotiating tactic at this point." VCSEL demand "looks to be skyrocketing" and the frustration in developing a secure second-source has likely caused Apple to explore internal development, write Donovan and Mullane. They understand Apple has looked into fabs in Taiwan to see about VCSEL development but note the earliest this could materialize is 2020-2021. This is likely more of a "call to arms" by Apple for Finisar, II-VI, and Lumentum to increase production to meet the demand, "or else face the consequences."
10/11/18
JPMS
10/11/18
UPGRADE
Target $80
JPMS
Overweight
JPMorgan upgrades Lumentum to Overweight after 19% selloff
JPMorgan analyst Samik Chatterjee upgraded Lumentum to Overweight from Neutral with an unchanged price target of $80. The shares closed yesterday down 3%, or $1.68, to $55.58. The 19% stock decline from the highs in late August, driven by concerns relative to U.S.-China trade, over-appreciates the "modest risks" for Lumentum, Chatterjee tells investors in a research note. He believes this creates an "attractive buying opportunity" to capitalize on the near-term improvement in the earnings outlook The analyst sees an improved outlook for Lumentum's telecom business on 5G investment tailwinds as well as benefits to pricing and market share in the datacom business. Further he expects "strong growth" in 3D sensing revenues on wider adoption of facial recognition technology on Apple (AAPL) iPhones and androids.
BABA Alibaba
$142.03

3.64 (2.63%)

10/10/18
KEYB
10/10/18
NO CHANGE
Target $215
KEYB
Overweight
Alibaba price target lowered to $215 from $220 at KeyBanc
KeyBanc analyst Hans Chung lowered his price target for Alibaba to $215 from $220 on lower expectations for Core Commerce, with downward revisions in CM and New Retail revenue. EBITA margin is lower as a result of lower revenue and higher content cost, he notes. Despite challenges for Alibaba to meet FY19 guidance given the near-term impact from the new Taobao upgrade and uncertainty around China's macro, Chung remains constructive on the longer-term opportunity and potential in Alibaba. He reiterates an Overweight rating on the shares.
10/10/18
MSCO
10/10/18
NO CHANGE
Target $220
MSCO
Overweight
Alibaba price target lowered to $220 ahead of earnings at Morgan Stanley
Morgan Stanley analyst Grace Chen stated in a preview of Alibaba's fiscal Q2 earnings report that she expects the Chinese e-commerce giant to reports sales 3% below consensus due to softer China online retail and digital entertainment sales. Factoring in a full quarter consolidation of loss-making Ele.me, higher investments and lighter customer management and commission revenue, Chen lowered her Q2 non-GAAP EBITA forecast 6% and cut her price target on Alibaba shares to $220 from $240. However, she keeps an Overweight rating on the stock, as Chen expects Alibaba's continued investments in "new retail" to help it widen its lead over rivals despite near-term margin pressure.
10/10/18
MKMP
10/10/18
NO CHANGE
Target $270
MKMP
Buy
Alibaba sees some 'evidence of soft patches', says MKM Partners
MKM Partners analyst Rob Sanderson kept his Buy rating and $270 price target on Alibaba ahead of its earnings for September quarter. The analyst says his conversations with the management indicates "some evidence of soft patches", but the company remains positive about the "general consumption trends". Sanderson adds that he still sees Alibaba shares among the "most attractive" in his mega-cap universe, stating that while macro concerns appear likely to persist, the impact from trade tensions appears "negligible". The analyst also contends that the company's "opportunity to digitize all consumption in China is many times larger than the company's current business".
10/12/18
STFL
10/12/18
NO CHANGE
Target $200
STFL
Buy
Stifel replaces Alibaba with Amazon on Select List after target drop
Stifel analyst Scott Devitt removed Alibaba (BABA) from his firm's Select List and replaced it with Amazon.com (AMZN). The analyst cites an "increasingly uncertain" China macro environment and near-term optimism for Amazon for the change. He also updated his Alibaba model, which resulted in near-term revenue growth assumptions that are 300 basis points lower versus his prior forecast. However, despite the difficult China market backdrop, Devitt continues to view Alibaba as a core long-term holding. He lowered his price target for the shares to $200 from $220 while keeping a Buy rating on the name.

TODAY'S FREE FLY STORIES

NCLH

Norwegian Cruise Line

$55.71

1.99 (3.70%)

10:32
02/21/19
02/21
10:32
02/21/19
10:32
Recommendations
Norwegian Cruise Line analyst commentary  »

Buckingham says backdrop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

  • 28

    May

BSX

Boston Scientific

$40.03

-0.1 (-0.25%)

10:30
02/21/19
02/21
10:30
02/21/19
10:30
Options
Bullish option flow in Boston Scientific »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

  • 18

    May

  • 28

    May

SNPS

Synopsys

$100.68

-2.3 (-2.23%)

10:26
02/21/19
02/21
10:26
02/21/19
10:26
Recommendations
Synopsys analyst commentary  »

Synopsys weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 03

    Mar

  • 08

    Mar

  • 14

    Mar

  • 17

    Mar

  • 16

    Jul

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

NWL

Newell Brands

$17.18

0.05 (0.29%)

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Periodicals
Newell Brands CEO faces board pressure following poor sales, WSJ reports »

Newell Brands CEO Michael…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
Morgan Stanley consumer goods analysts to hold analyst/industry conference call »

Executive Director of…

BIIB

Biogen

$323.78

-11.23 (-3.35%)

, ESALY

Eisai

$0.00

(0.00%)

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
JPMorgan large-cap biotech analysts to hold an analyst/industry conference call »

Large Cap Biotech Analyst…

BIIB

Biogen

$323.78

-11.23 (-3.35%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 28

    May

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
JPMorgan retail analysts to hold an analyst/industry conference call »

Retail Analysts Boss and…

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
Morgan Stanley sports/footwear analyst to hold analyst/industry conference call »

Sports & Footwear…

EEM

iShares MSCI Emerging Markets ETF

$42.48

-0.175 (-0.41%)

10:20
02/21/19
02/21
10:20
02/21/19
10:20
Options
Size three-way spread in iShares Emerging Markets Fund as shares tick lower »

Size three-way spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
02/21/19
02/21
10:17
02/21/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
02/21/19
02/21
10:16
02/21/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
02/21/19
02/21
10:15
02/21/19
10:15
General news
U.S. leading index dipped 0.1% to 111.3 in January »

U.S. leading index dipped…

10:15
02/21/19
02/21
10:15
02/21/19
10:15
General news
Breaking General news story  »

Week of 2/15 EIA Natural…

HOME

At Home Group

$23.84

0.01 (0.04%)

, HLIT

Harmonic

$5.51

0.19 (3.57%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

HOME

At Home Group

$23.84

0.01 (0.04%)

HLIT

Harmonic

$5.51

0.19 (3.57%)

ATKR

Atkore

$24.08

-0.09 (-0.37%)

BTX

BioTime

$1.24

0.08 (6.90%)

VRCA

Verrica Pharmaceuticals

$10.99

(0.00%)

APHA

Aphria

$10.40

0.24 (2.36%)

KSHB

KushCo Holdings

$0.00

(0.00%)

HEXO

HEXO Corp

$6.11

0.13 (2.17%)

CGC

Canopy Growth

$45.44

-0.74 (-1.60%)

ACB

Aurora Cannabis

$7.18

0.12 (1.70%)

TLRY

Tilray

$80.25

-0.82 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 01

    Mar

  • 07

    Mar

  • 18

    Mar

  • 18

    Mar

GRMN

Garmin

$82.02

-1 (-1.20%)

, BIIB

Biogen

$324.13

-10.88 (-3.25%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

GRMN

Garmin

$82.02

-1 (-1.20%)

BIIB

Biogen

$324.13

-10.88 (-3.25%)

FARO

Faro Technologies

$45.51

1.73 (3.95%)

DHI

D.R. Horton

$39.91

0.04 (0.10%)

LEN

Lennar

$49.12

0.16 (0.33%)

GIS

General Mills

$46.68

-0.26 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 28

    May

CAJ

Canon

$29.10

-0.02 (-0.07%)

, SAM

Boston Beer

$302.00

34.05 (12.71%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

CAJ

Canon

$29.10

-0.02 (-0.07%)

SAM

Boston Beer

$302.00

34.05 (12.71%)

X

U.S. Steel

$24.25

0.25 (1.04%)

FARO

Faro Technologies

$45.51

1.73 (3.95%)

AAN

Aaron's

$54.10

0.46 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$18.86

-0.57 (-2.93%)

10:10
02/21/19
02/21
10:10
02/21/19
10:10
Options
Put buyers in Kemet Corp as shares slip »

Put buyers in Kemet Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
02/21/19
02/21
10:10
02/21/19
10:10
General news
U.S. existing home sales dropped 1.2% in January to 4.94 M »

U.S. existing home sales…

CPRX

Catalyst Pharmaceuticals

$2.80

0.04 (1.45%)

10:08
02/21/19
02/21
10:08
02/21/19
10:08
On The Fly
Catalyst Pharmaceuticals defends pricing for Firdapse after Sanders slams company »

Nearly three weeks after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:05
02/21/19
02/21
10:05
02/21/19
10:05
General news
Leading Indicators data reported »

January Leading…

10:05
02/21/19
02/21
10:05
02/21/19
10:05
General news
FX Action: The dollar »

FX Action: The dollar was…

10:03
02/21/19
02/21
10:03
02/21/19
10:03
General news
Existing Home Sales data reported »

January Existing Home…

APYX

Apyx Medical

$8.36

-0.16 (-1.88%)

10:02
02/21/19
02/21
10:02
02/21/19
10:02
Hot Stocks
Apyx Medical mentioned cautiously in a Seeking Alpha article 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 13

    Mar

  • 21

    Mar

ICLR

Icon

$140.52

-5.09 (-3.50%)

10:01
02/21/19
02/21
10:01
02/21/19
10:01
Hot Stocks
Icon acquires MolecularMD, terms not disclosed »

MolecularMD announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 13

    Mar

EVTC

Evertec

$27.23

-3.42 (-11.16%)

10:00
02/21/19
02/21
10:00
02/21/19
10:00
Hot Stocks
Evertec falls -10.9% »

Evertec is down -10.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 27

    Feb

  • 12

    Mar

  • 22

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.